Grufity logoGrufity logo

TNDM

41.18USD+1.64(+4.15%)Market Closed

Tandem Diabetes Care Inc

Market Summary

USD41.18+1.64Market Closed
4.15%

TNDM Alerts

TNDM Stock Price

RSI Chart

Valuation

Market Cap

3.6B

Price/Earnings

-273.58

Price/Sales

4.7

Price/Cashflow

48.37

MarketCap/EBT

-289.48

Price/Sales

Profitability

EBT Margin

-1.63%

Return on Equity

-2.93%

Return on Assets

-1.27%

Fundamentals

Revenue

Revenue (TTM)

790.7M

Revenue Y/Y

13.87%

Revenue Q/Q

2.14%

Earnings

Earnings (TTM)

-67.9M

Earnings Y/Y

-945.18%

Earnings Q/Q

-225.25%

Price Action

52 Week Range

33.52155.86
(Low)(High)

Last 7 days

6.7%

Last 30 days

-26.6%

Last 90 days

-10.2%

Trailing 12 Months

-68.2%

Financial Health

Current Ratio

6

Debt/Equity

0.19

Debt/Cashflow

1.35

Investor Care

Shares Dilution (1Y)

1.21%

Diluted EPS (TTM)

-1.07

Peers (Alternatives to Tandem Diabetes Care)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-9.62% 40.13%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
-0.86% -5.85%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
7.57% -20.23%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
0.88% 0.27%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
1.46% 13.53%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
6.93% -30.81%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
5.68% 11.07%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
16.86% -20.83%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-17.36% 8.54%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-26.60% -68.24%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
13.24% 18.65%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
-7.32% -10.12%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.20% -15.61%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-9.99% -42.69%
-16.43
2.57
-8.79% -175.19%

Financials for Tandem Diabetes Care

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue3.3%791766738703661
Gross Profit1.9%411404394376353
Operating Expenses15.3%474411383354324
  S&GA Expenses6.6%309290276262245
  R&D Expenses12.2%1201079280
Earnings Before Taxes-427.4%-65.64-12.4551622
Net Income-415.9%-67.93-13.1761622
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets1.1%1,0481,0371,015905850
  Current Assets-0.1%834835818812755
    Cash Equivalents7.7%1241159471112
  Inventory18.9%10588806966
  Net PPE23.8%7359505050
Liabilities6.6%626587578472461
  Current Liabilities24.7%174139132132120
Shareholder's Equity-6.2%422450437433390
  Retained Earnings-7.4%-713.34-664.37-649.31-634.59-645.40
  Additional Paid-In Capital2.0%1,1401,1181,0901,0681,035
Accumulated Depreciation-49----
Shares Outstanding0.1%6464646463
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-13.7%647496111107
  Share Based Compensation9.2%7871666157
Cashflow From Investing24.0%-79.43-104.47-175.58-186.88-169.68
Cashflow From Financing-42.4%2746525245

Risks

What is the probability of a big loss on TNDM?

100%


Probability that Tandem Diabetes Care stock will be more than 20% underwater in next one year

81.2%


Probability that Tandem Diabetes Care stock will be more than 30% underwater in next one year.

45.8%


Probability that Tandem Diabetes Care stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TNDM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Tandem Diabetes Care was unfortunately bought at previous high price.

Returns

Cumulative Returns on TNDM

-12.3%


7-Year Cumulative Returns

74.0%


5-Year Cumulative Returns

-15.8%


3-Year Cumulative Returns

What are the long-term rolling returns for TNDM?

FIve years rolling returns for Tandem Diabetes Care.

Which funds bought or sold TNDM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
460,000
460,000
-%
2022-11-21
FourThought Financial, LLC
-
-
-7,000
5,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-998,000
3,847,000
0.01%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-192,000
-
-%
2022-11-16
Front Row Advisors LLC
NEW
-
5,000
5,000
-%
2022-11-16
Retirement Systems of Alabama
REDUCED
-0.22
-964,000
4,023,000
0.02%
2022-11-16
Neo Ivy Capital Management
SOLD OFF
-100
-1,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
ADDED
13.26
-2,000
14,000
-%
2022-11-15
Baird Financial Group, Inc.
REDUCED
-28.69
-714,000
973,000
-%
2022-11-15
JANE STREET GROUP, LLC
ADDED
21.41
-40,000
2,119,000
-%

1–10 of 45

Latest Funds Activity

Are funds buying TNDM calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TNDM

Tandem Diabetes Care News

Stocks Register

Investors Take Advantage Of Tandem Diabetes Care Inc.'s (NASDAQ: TNDM) -0.03% Loss.17 hours ago

Yahoo Finance

TNDM Fair Value

Recent SEC filings of Tandem Diabetes Care

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 02, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for TNDM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
Vosseller Leigh
SOLD FOR TAXES
-2,409.39
42.27
-57
EVP & CHIEF FINANCIAL OFFICER
2022-11-15
BERGER DAVID B
SOLD FOR TAXES
-3,423.87
42.27
-81
EVP & Chief Operating Officer
2022-11-15
HANSEN BRIAN B
SOLD FOR TAXES
-2,240.31
42.27
-53
EVP & CHIEF COMMERCIAL OFFICER
2022-11-15
Morrison Susan
ACQUIRED
-
-
163
EVP & Chief Admin. Officer
2022-11-15
Carpenter Rick
ACQUIRED
11,964.7
35.93
333
Chief Technical Officer
2022-11-15
Morrison Susan
SOLD FOR TAXES
-1,986.69
42.27
-47
EVP & Chief Admin. Officer
2022-11-15
Sheridan John F
ACQUIRED
-
-
793
PRESIDENT & CEO
2022-11-15
Vosseller Leigh
ACQUIRED
-
-
163
EVP & CHIEF FINANCIAL OFFICER
2022-11-15
Hansen Shannon Marie
ACQUIRED
12,000.6
35.93
334
SVP & General Counsel
2022-11-15
Gasser Elizabeth Anne
ACQUIRED
-
-
163
EVP, Chief Strategy Officer

1–10 of 50

John F. Sheridan
2000
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Sales$ 204,547$ 179,627$ 580,716$ 492,803
Cost of sales100,12282,882283,252230,317
Gross profit104,42596,745297,464262,486
Operating expenses:    
Selling, general and administrative84,10464,923237,989190,009
Research and development36,79824,102103,52962,562
Acquired in-process research and development expenses31,016031,0160
Total operating expenses151,91889,025372,534252,571
Operating income (loss)(47,493)7,720(75,070)9,915
Other income (expense), net:    
Interest income and other, net1,708312,858721
Interest expense(1,576)(1,511)(4,629)(4,526)
Change in fair value of common stock warrants12(392)103(1,354)
Total other income (expense), net144(1,872)(1,668)(5,159)
Income (loss) before income taxes(47,349)5,848(76,738)4,756
Income tax expense (benefit)1,621542,003(2)
Net income (loss)(48,970)5,794(78,741)4,758
Other comprehensive income (loss):    
Unrealized gain (loss) on short-term investments(258)8(3,899)(81)
Foreign currency translation loss(524)(23)(549)(125)
Comprehensive income (loss)$ (49,752)$ 5,779$ (83,189)$ 4,552
Net income (loss) per share, basic (in dollars per share)$ (0.76)$ 0.09$ (1.23)$ 0.08
Net income (loss) per share, diluted (in dollars per share)$ (0.76)$ 0.09$ (1.23)$ 0.07
Weighted average shares used to compute basic net income (loss) per share (in shares)64,23663,16764,06662,780
Weighted average shares used to compute diluted net income (loss) per share (in shares)64,23764,78464,06764,198

TNDM Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 123,786$ 71,181
Short-term investments484,941552,630
Accounts receivable, net112,805110,725
Inventories104,77468,551
Prepaid and other current assets7,9978,433
Total current assets834,303811,520
Property and equipment, net72,90550,386
Operating lease right-of-use assets116,47427,503
Other long-term assets23,83815,728
Total assets1,047,520905,137
Current liabilities:  
Accounts payable61,53128,032
Accrued expenses7,8989,419
Employee-related liabilities47,96751,556
Operating lease liabilities12,1209,279
Deferred revenue12,97410,182
Other current liabilities31,14023,388
Total current liabilities173,630131,856
Convertible senior notes, net - long-term282,787281,467
Operating lease liabilities - long-term127,10923,922
Deferred revenue - long-term19,14316,940
Other long-term liabilities23,02917,840
Total liabilities625,698472,025
Commitments and contingencies (Note 12)00
Stockholders’ equity:  
Common stock, $0.001 par value; 200,000 shares authorized, 64,265 and 63,833 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.6464
Additional paid-in capital1,140,1581,068,259
Accumulated other comprehensive loss(5,064)(616)
Accumulated deficit(713,336)(634,595)
Total stockholders’ equity421,822433,112
Total liabilities and stockholders’ equity$ 1,047,520$ 905,137